ABINGDON, England--(BUSINESS WIRE)--Atopix Therapeutics Ltd (“Atopix”), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, today announced the addition of SR One to its investor syndicate and the appointment of Dr Deborah Harland, Partner, SR One to the Board of Directors, following an extension to its Series A financing. The additional funds provided by SR One will be used to complete the evaluation of Atopix’s lead CRTH2 antagonist OC459 in atopic dermatitis and to assess the safety and pharmacokinetic profile of its highly potent back-up molecule ATX2417 in Phase I studies.
Atopix will continue to explore the utility of these compounds in patients with diseases characterised by an overactive Th2 immune response, such as severe eosinophilic asthma.
Help employers find you! Check out all the jobs and post your resume.
